A detailed history of Los Angeles Capital Management LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 52,863 shares of DNLI stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,863
Previous 55,612 4.94%
Holding current value
$1.42 Million
Previous $1.14 Million 7.54%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$14.96 - $23.22 $41,125 - $63,831
-2,749 Reduced 4.94%
52,863 $1.23 Million
Q1 2024

Apr 05, 2024

BUY
$15.83 - $23.35 $143,324 - $211,410
9,054 Added 19.45%
55,612 $1.14 Million
Q4 2023

Feb 06, 2024

BUY
$16.2 - $23.18 $9,007 - $12,888
556 Added 1.21%
46,558 $999,000
Q3 2023

Nov 06, 2023

BUY
$20.63 - $30.17 $21,578 - $31,557
1,046 Added 2.33%
46,002 $949,000
Q2 2023

Aug 03, 2023

BUY
$23.37 - $32.96 $618,113 - $871,759
26,449 Added 142.91%
44,956 $1.33 Million
Q1 2023

May 04, 2023

SELL
$21.91 - $32.67 $52,474 - $78,244
-2,395 Reduced 11.46%
18,507 $426,000
Q4 2022

Feb 06, 2023

SELL
$26.28 - $33.92 $573,928 - $740,778
-21,839 Reduced 51.1%
20,902 $581,000
Q3 2022

Nov 02, 2022

SELL
$25.97 - $38.53 $30,592 - $45,388
-1,178 Reduced 2.68%
42,741 $1.31 Million
Q2 2022

Aug 05, 2022

BUY
$20.88 - $35.19 $34,806 - $58,661
1,667 Added 3.95%
43,919 $1.29 Million
Q1 2022

May 06, 2022

BUY
$29.0 - $47.27 $33,640 - $54,833
1,160 Added 2.82%
42,252 $1.36 Million
Q4 2021

Feb 03, 2022

SELL
$42.59 - $55.02 $18,313 - $23,658
-430 Reduced 1.04%
41,092 $1.83 Million
Q3 2021

Nov 08, 2021

BUY
$48.48 - $78.23 $392,203 - $632,880
8,090 Added 24.2%
41,522 $2.1 Million
Q2 2021

Aug 05, 2021

BUY
$50.3 - $78.44 $827,787 - $1.29 Million
16,457 Added 96.95%
33,432 $2.62 Million
Q1 2021

May 05, 2021

SELL
$53.8 - $81.53 $220,633 - $334,354
-4,101 Reduced 19.46%
16,975 $969,000
Q4 2020

Feb 04, 2021

BUY
$36.89 - $93.56 $443,602 - $1.13 Million
12,025 Added 132.86%
21,076 $1.77 Million
Q3 2020

Nov 02, 2020

SELL
$23.13 - $38.84 $157,954 - $265,238
-6,829 Reduced 43.0%
9,051 $324,000
Q2 2020

Aug 05, 2020

SELL
$16.01 - $28.82 $66,761 - $120,179
-4,170 Reduced 20.8%
15,880 $383,000
Q1 2020

May 04, 2020

BUY
$14.2 - $27.98 $284,710 - $560,999
20,050 New
20,050 $351,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.